Cabozantinib improves progression-free survival in metastatic renal cell carcinoma
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented today at the ESMO 2016 Congress in Copenhagen.
Oct 10, 2016
0
5